GlassScriptPhysician profile
Naeem Aslam
NPI 1750347902
$6,054.88
in general payments reported to CMS, 2019-2025
33 companies · $790 in 2025
The $790 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $557 · 2021: $731 · 2022: $987 · 2023: $1,339 · 2024: $1,090 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,219.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,666.51 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Gilead Sciences, INC. | $561.71 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $445.02 | 2024-2025 | Zenpep, Vowst |
| Janssen Biotech, INC. | $442.89 | 2022-2025 | Stelara, Remicade, Simponi |
| Ardelyx, INC. | $418.72 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $337.12 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $317.54 | 2021-2024 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $223.97 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $192.68 | 2019-2023 | Entyvio |
| Pfizer INC. | $181.39 | 2022-2025 | |
| Capsovision, INC. | $162.10 | 2023-2025 | Capsocam Plus |
| Redhill Biopharma INC. | $132.52 | 2020-2023 | |
| Genzyme Corporation | $129.49 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $121.19 | 2022 | |
| Braintree Laboratories, INC. | $120.69 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $118.38 | 2019 | |
| Ironwood Pharmaceuticals, INC | $64.64 | 2019-2021 | |
| Qol Medical, LLC | $53.87 | 2020-2022 | |
| Concordia Pharmaceuticals INC. | $45.06 | 2019 | |
| Madrigal Pharmaceuticals | $37.97 | 2025 | Rezdiffra |
| Lilly USA, LLC | $37.91 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $35.54 | 2020-2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $33.83 | 2024 | Voquezna |
| Celgene Corporation | $24.77 | 2021-2022 | |
| Conmed Corporation | $24.05 | 2021 | |
| Echosens North America, INC. | $20.11 | 2024 | Fibroscan |
| Ferring Pharmaceuticals INC. | $19.10 | 2023 | Rebyota |
| Micro-Tech Endoscopy USA, INC. | $16.64 | 2025 | Lesionhunter |
| Vivus LLC | $16.08 | 2021 | |
| Alfasigma USA, INC. | $15.56 | 2020 | |
| Apollo Endosurgery US INC | $15.15 | 2019 | |
| Shionogi INC | $11.40 | 2019 | |
| Merck Sharp & Dohme LLC | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naeem Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.